Market Place
Sourcing Support
Bial Portela`s Biologic Optilyv (Opicapone) Receives Approval in Europe
07 Mar 2022 //
EMA
Sunovion and BIAL Enter European Licensing Agreement
02 Sep 2021 //
BUSINESSWIRE
NICE, PHE publish antimicrobial prescribing guideline on C. difficile infection
22 Jul 2021 //
PHARMATIMES
Bial and Medis to enter partnership on CNS treatments
20 Jul 2021 //
PHARMAFILE
BIAL and Medis entered into a partnership for innovative medicines for Tcns
19 Jul 2021 //
THEPHARMALETTER
Entasis Introduces ETX0462 Targeting Multidrug-Resistant Gram-ve Pathogens
01 Jul 2021 //
GLOBENEWSWIRE
Novome Initiates Ph1/2a Study to Evaluate Therapeutically Engineered Bacteria
30 Jun 2021 //
GLOBENEWSWIRE
Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide
28 Jun 2021 //
GLOBENEWSWIRE
OpGen Group Company Ares Genetics Presents R&D Pipeline Updates
28 Jun 2021 //
GLOBENEWSWIRE
BIAL Goes Global With New US Research Center and Acquisition of Parkinson`s
01 Oct 2020 //
BUSINESSWIRE
Aptiom® (Eslicarbazepine Acetate) : Bial - Portela & CA S.A v. Hetero Labs
08 Mar 2018 //
PATENT LITIGATION
Aptiom® (Eslicarbazepine Acetate) : Bial - Portela v. Jubilant Life Sciences
01 Mar 2018 //
PATENT LITIGATION
Aptiom® (Eslicarbazepine Acetate):Bial - Portela & CA S.A. v. Jubilant
01 Mar 2018 //
PATENT LITIGATION
Aptiom® (Eslicarbazepine Acetate):Bial - Portela & CA S.A. v. Alkem Laboratories
22 Feb 2018 //
PATENT LITIGATION
Zebinix non-inferior to current standard of care in epilepsy
02 Feb 2018 //
PHARMA TIMES
Real world data back use of Eisai, Bial’s Zebinix in epilepsy
15 Dec 2017 //
PHARMA TIMES
Neurocrine & BIAL Announce North American Licensing Agreement for Opicapone
09 Feb 2017 //
PR NEWSIWRE
After trial death and before Trump change, a call for drug approval reform
30 Jan 2017 //
CNN
EMA to hold major review after fatal French trial
25 May 2016 //
FIERCE BIOTECH
Scientists Speculate On What Caused The Bial Drug Testing Tragedy In France
19 Jan 2015 //
FORBES PHARMA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.